ENA Respiratory
PrivateLast Round
Series B
Oct 22, 2025
Total Funding Raised
$46.83M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
ENA Respiratory is a clinical-stage pharmaceutical company developing antiviral host defence enhancers to combat respiratory viral infections by boosting the body's local innate immune response.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ENA Respiratory Comparables
Compare ENA Respiratory with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| NorthLinks Bio | 85% | |
| Leyden Labs | 79% | |
| SaNOtize Research & Development Corp. | 77% |
ENA Respiratory Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Oct 22, 2025 | ||||
| Grant | Sep 5, 2024 | ||||
| Grant | Aug 29, 2023 | ||||
| Grant | Jan 9, 2023 | ||||
| VC Round | Jun 15, 2021 | ||||
Series A Extension | Sep 28, 2020 |
Key People
Founding team and executive leadership
ENA Respiratory Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Flu Lab | Series B |
| Minderoo Foundation | VC Round |
| United States Department of Defense | Grant |
| Hostplus Superannuation Fund | Series A Extension |
| Bill & Melinda Gates Foundation | Series B |
| Uniseed | Series A, Series A Extension, Series B, VC Round |
| Stoic Venture Capital | Series A Extension, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 41% MoM.
- Jun 1, 2025
Monthly visitors grew 100% MoM, reaching 1.6K.
ENA Respiratory Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about ENA Respiratory's valuation, stock price, and market status.
Is ENA Respiratory a public or private company?
ENA Respiratory is a private company.
What is the current stock price of ENA Respiratory?
ENA Respiratory is a private company with no public stock price. No recent secondary market data is available.
How much is ENA Respiratory worth (valuation)?
Valuation information for ENA Respiratory is not publicly available.
Can I buy ENA Respiratory stock?
ENA Respiratory shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was ENA Respiratory's last funding round?
ENA Respiratory's most recent funding round was Series B on October 22, 2025.
Who are the main investors in ENA Respiratory?
Key investors in ENA Respiratory include Minderoo Foundation, Brandon Capital.
Will ENA Respiratory IPO soon?
No public IPO plans have been announced for ENA Respiratory.
How can I track ENA Respiratory secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor ENA Respiratory's secondary market activity and sign up for updates.